Expertise in
145
conditions

Dr. Jaswinder Singh

Hematology | Oncology
4901 College Blvd, 
Leawood, KS 
On Staff At
Expertise in
145
conditions
4901 College Blvd, 
Leawood, KS 

Overview

Jaswinder Singh is a Hematologist and an Oncologist practicing medicine in Leawood, Kansas.

Dr. Singh is highly rated in 145 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MO

Hospital Affiliations

Cass Regional Medical Center
Western Missouri Medical Center
Research Medical Center
Bates County Memorial Hospital
Golden Valley Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ascentist Physicians Group
4901 College Blvd, Leawood, KS 66211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
Enrollment Status: No_longer_available
Publish Date: April 12, 2024
Intervention Type: Drug
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
Enrollment Status: Withdrawn
Publish Date: February 15, 2019
Intervention Type: Other, Device
Study Phase: Not Applicable
View 6 Less Clinical Trials

7 Total Publications

Comment on "The optimal labelling method for artificial intelligence-assisted polyp detection in colonoscopy".
Comment on "The optimal labelling method for artificial intelligence-assisted polyp detection in colonoscopy".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: March 09, 2026
Similar Doctors
Expertise in
67
conditions
Dr. Jacob Smeltzer
Hematology | Oncology
Expertise in
67
conditions
Dr. Jacob Smeltzer
Hematology | Oncology

AdventHealth Medical Group Hematology Oncology At Shawnee Mission

9100 W 74th St, 
Merriam, KS 
 (54.5 miles away)
913-632-9100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jacob Smeltzer is a Hematologist and an Oncologist practicing medicine in Merriam, Kansas. Dr. Smeltzer is highly rated in 67 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Colorectal Cancer, Neuroendocrine Tumor, and Large-Cell Immunoblastic Lymphoma.

Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology
Expertise in
51
conditions
Dr. Abdulraheem Yacoub
Hematology

Clinical Research Center

4350 Shawnee Mission Parkway, 
Fairway, KS 
 (52.5 miles away)
913-588-1227
Experience:
23+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Abdulraheem Yacoub is a Hematologist practicing medicine in Fairway, Kansas. He has been practicing medicine for over 23 years. Dr. Yacoub is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Yacoub is board certified in American Board Of Internal Medicine, Hematology - 2012 and American Board Of Internal Medicine, Medical Oncology - 2011. Dr. Yacoub is currently accepting new patients.

Expertise in
52
conditions
Dr. Muhammad A. Salamat
Hematology | Oncology
Expertise in
52
conditions
Dr. Muhammad A. Salamat
Hematology | Oncology

Prime Healthcare Physician Services Providence

8919 Parallel Pkwy Ste 326, 
Kansas City, KS 
 (61.4 miles away)
913-596-5010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Muhammad Salamat is a Hematologist and an Oncologist practicing medicine in Kansas City, Kansas. Dr. Salamat is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC).

Frequently Asked Questions about Dr. Jaswinder Singh

How do I make an appointment with Dr. Jaswinder Singh?

You can book an appointment with Dr. Jaswinder Singh by calling their office at 913-529-1801. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jaswinder Singh a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jaswinder Singh is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jaswinder Singh specialize in?

While Dr. Jaswinder Singh is a Hematology, they have specific expertise in Pancreatic Cancer, Colorectal Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jaswinder Singh participate in research or clinical trials?

Yes. Dr. Jaswinder Singh has published 7 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Jaswinder Singh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jaswinder Singh accept my insurance?

Dr. Jaswinder Singh accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-529-1801 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
    View All 51 Distinguished Conditions
    View All 94 Advanced Conditions
    View All 199 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile